Long-Read Sequencing for Biopharma and Biotech
Biopharma and biotech programs increasingly need molecular information that extends beyond short fragments or single-variant calls. Long-read sequencing can resolve complete DNA and RNA molecules, complex rearrangements, phased haplotypes, full-length transcripts, vector structures, and selected native modification patterns in a single-molecule context.
CD Genomics brings together complementary PacBio HiFi and Oxford Nanopore Technologies (ONT) capabilities to support research programs from discovery through molecular characterization. This page provides a direct entry point to our long-read solutions for biomarker discovery, construct and cell-line verification, gene editing, mRNA vaccines, antibody development, and gene therapy.
Explore Our Biopharma & Biotech Solutions
Biomarker Discovery
Resolve structural variants, phased haplotypes, full-length isoforms, fusion transcripts, repeat-associated features, and modification-linked candidates when short-read discovery leaves the underlying molecular structure unresolved.
Plasmid & Cell Line Verification
Characterize full plasmid sequence and architecture, transgene integration sites, copy structures, rearrangements, and clone-to-clone or cell-bank consistency for research-stage production cell-line development.
Gene-Editing Characterization
Examine intended edits together with large deletions, insertions, inversions, complex rearrangements, donor or vector integration, allele phasing, and selected structural off-target events that may be missed by short amplicons.
mRNA Vaccine Characterization
Apply long-read RNA strategies to research questions involving full-length transcript identity, end heterogeneity, poly(A) tail characteristics, transcript integrity, sequence variants, and modification-aware analysis where appropriate.
Antibody Discovery & Development
Profile full-length B-cell receptor sequences, clonotypes, somatic hypermutation, isotypes, clonal lineages, paired-chain information in suitable single-cell designs, and complete antibody-library inserts for candidate discovery.
Gene Therapy & AAV Characterization
Characterize AAV vector-genome identity, full and partial genome structures, rearrangements, vector-associated non-target DNA, host-vector junctions, and integration architecture across vector-development research.
How Long-Read Sequencing Supports Biopharma R&D
The value of long-read sequencing is not simply longer reads. It is the ability to preserve molecular context. A single molecule can connect a structural breakpoint with its flanking sequence, phase multiple variants on one haplotype, span a complete transcript or antibody construct, or show how vector-derived and host-derived sequences are physically linked.
- Genome structure: resolve complex SVs, repeats, integrations, rearrangements, and long-range haplotypes.
- Full-length RNA: examine transcript isoforms, fusions, transcript ends, poly(A) features, and native RNA information when the workflow supports it.
- Single-molecule context: connect sequence, structure, phase, and selected modification signals on the same DNA or RNA molecules.
- Development-stage flexibility: support studies beginning with purified nucleic acids, constructs, cell lines, vector preparations, tissues, or existing libraries and data.
PacBio HiFi and ONT are used as complementary platforms rather than interchangeable labels. We select the sequencing strategy according to the molecule, required read span, accuracy needs, native-molecule requirements, and the biological question.
One Long-Read Partner Across Multiple Development Questions
Biopharma projects often move across molecular layers: a biomarker candidate may lead to a gene-editing experiment; an edited clone may become a production cell line; a vector or mRNA construct may then require deeper structural characterization. Using a connected long-read framework makes it easier to keep sequence definitions, reference constructs, sample metadata, and downstream analyses consistent as the research question changes.
CD Genomics provides end-to-end project support from library strategy and sequencing through bioinformatics and interpretation. Final assay design, sample requirements, and reporting depth are defined on the individual solution page and confirmed for each project.
For Research Use Only. Not for use in diagnostic or clinical procedures.